Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed that the median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as a monotherapy.

The combination reduced the risk of death compared to treatment with vemurafenib alone.

The results, which was presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois also showed that the two . . .